INVENTIONS FOR LICENSE

MCL 1629.0: Compounds for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Perry Renshaw, M.D., Ph.D.

Treatment of ADHD

Background and Description

Functional MRI experiments indicate that symptoms of hyperactivity and inattention are correlated with measures of blood flow within the putamen nuclei (strongly dopaminergic brain regions), and in addition, currently used agents for ADHD are known to increase blood flow. The invention comprises the use of a class of compounds known to have dopaminergic activity, as a treatment for ADHD that may avoid some of the side effects of existing therapies for this disorder.

Potential Commercial Uses

The invention comprises a method of treating attention deficit disorders, by administering a compound known to have dopaminergic activity. It is believed that the compounds of this invention can be used on ADHD patients without many of the side effects that are seen with stimulant therapies currently in use.

Publication and Patent Status

McLean Hospital has filed U.S. and European patent applications claiming this invention.

Licenses Available

Exclusive licenses to this technology are available in certain fields of use.

For more information, please contact:

Anne Ritter, Licensing Manager
Partners Research Ventures and Licensing
amritter@partners.org
(617) 954-9529